T2 BIOSYSTEMS INC (TTOO) Stock Price, Forecast & Analysis
USA - NASDAQ:TTOO - US89853L3024 - Common Stock
TTOO Key Statistics, Chart & Performance
The current stock price of TTOO is 0.134 USD. In the past month the price decreased by -58.13%. In the past year, price decreased by -97.54%.
TTOO Latest News, Press Relases and Analysis
TTOO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25.02 | 417.70B | ||
| AMGN | AMGEN INC | 15.74 | 185.33B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.81 | 110.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 76.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 902.74 | 60.35B | ||
| INSM | INSMED INC | N/A | 43.16B | ||
| NTRA | NATERA INC | N/A | 29.91B | ||
| BIIB | BIOGEN INC | 10.04 | 24.63B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.1 | 21.61B | ||
| INCY | INCYTE CORP | 16.05 | 20.12B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 32.98 | 13.67B |
Related stock screener links
About TTOO
Company Profile
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Company Info
T2 BIOSYSTEMS INC
101 Hartwell Ave
Lexington MASSACHUSETTS 02421 US
CEO: John Sperzel
Employees: 113
Phone: 17814571200
T2 BIOSYSTEMS INC / TTOO FAQ
Can you describe the business of T2 BIOSYSTEMS INC?
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
What is the current price of TTOO stock?
The current stock price of TTOO is 0.134 USD. The price decreased by -31.07% in the last trading session.
Does T2 BIOSYSTEMS INC pay dividends?
TTOO does not pay a dividend.
What is the ChartMill technical and fundamental rating of TTOO stock?
TTOO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is T2 BIOSYSTEMS INC (TTOO) stock traded?
TTOO stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for T2 BIOSYSTEMS INC?
The Revenue of T2 BIOSYSTEMS INC (TTOO) is expected to grow by 51.43% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of T2 BIOSYSTEMS INC (TTOO)?
You can find the ownership structure of T2 BIOSYSTEMS INC (TTOO) on the Ownership tab.
TTOO Technical Analysis
TTOO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TTOO. TTOO has a bad profitability rating. Also its financial health evaluation is rather negative.
TTOO Financial Highlights
Over the last trailing twelve months TTOO reported a non-GAAP Earnings per Share(EPS) of -7.82. The EPS increased by 97.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -237.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TTOO Forecast & Estimates
6 analysts have analysed TTOO and the average price target is 5.1 USD. This implies a price increase of 3705.97% is expected in the next year compared to the current price of 0.134.
For the next year, analysts expect an EPS growth of 83.26% and a revenue growth 51.43% for TTOO